Get the Stockscreener App
5.36
3.17%
-0.15
Optimizerx Corp stock is traded at $5.36, with a volume of 45,286.
It is down -3.17% in the last 24 hours and down -8.33% over the past month.
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
See More
Previous Close:
$5.51
Open:
$5.51
24h Volume:
45,286
Relative Volume:
0.16
Market Cap:
$101.50M
Revenue:
$62.81M
Net Income/Loss:
$-13.75M
P/E Ratio:
-6.70
EPS:
-0.8
Net Cash Flow:
$153.00K
1W Performance:
-3.87%
1M Performance:
-8.33%
6M Performance:
-35.57%
1Y Performance:
-64.57%
1-Day Range:
$5.20
$5.51
1-Week Range:
$5.20
$6.03
52-Week Range:
$3.78
$16.64
Optimizerx Corp Stock (OPRX) Company Profile
Name
Optimizerx Corp
Sector
Industry
Phone
248-651-6558
Address
260 CHARLES STREET, WALTHAM, MI
Compare OPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OPRX
Optimizerx Corp
|
5.335 | 101.50M | 62.81M | -13.75M | 153.00K | -0.80 |
|
VEEV
Veeva Systems Inc
|
236.76 | 38.87B | 2.66B | 665.91M | 1.08B | 4.05 |
|
SOLV
Solventum Corp
|
73.15 | 12.92B | 8.26B | 66.00M | 1.17B | 0.3682 |
|
DOCS
Doximity Inc
|
79.32 | 10.88B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
68.06 | 10.23B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
111.74 | 9.71B | 1.15B | 96.70M | -161.99M | 1.09 |
Optimizerx Corp Stock (OPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-20-24 | Initiated | Stephens | Equal-Weight |
| Jul-25-24 | Resumed | B. Riley Securities | Buy |
| Apr-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Feb-02-23 | Resumed | B. Riley Securities | Buy |
| Nov-01-22 | Initiated | Stifel | Buy |
| Jul-15-22 | Initiated | SVB Leerink | Outperform |
| Oct-18-21 | Resumed | B. Riley Securities | Buy |
| Apr-13-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-03-19 | Initiated | William Blair | Outperform |
View All
Optimizerx Corp Stock (OPRX) Latest News
Where OptimizeRx Stands With Analysts - Benzinga
JPMorgan Chase & Co. Sells 104,750 Shares of OptimizeRx Co. (NASDAQ:OPRX) - MarketBeat
Whetstone Capital Discloses 8.2% Stake in OptimizeRx, Urges Strategic Alternatives - Yahoo Finance
OptimizeRx Co. (NASDAQ:OPRX) Receives $9.06 Average Target Price from Brokerages - MarketBeat
OptimizeRx Co. (NASDAQ:OPRX) Receives $9.06 Consensus Target Price from Brokerages - Defense World
Chuck Royce's Strategic Acquisition of OptimizeRx Corp Shares - GuruFocus.com
OptimizeRx (NASDAQ:OPRX) adds US$12m to market cap in the past 7 days, though investors from three years ago are still down 87% - Simply Wall St
Strong week for OptimizeRx (NASDAQ:OPRX) shareholders doesn't alleviate pain of three-year loss - Yahoo Finance
Contrasting Ucommune International (NASDAQ:UK) and OptimizeRx (NASDAQ:OPRX) - Defense World
OptimizeRx Co. (NASDAQ:OPRX) Shares Sold by Jane Street Group LLC - Defense World
OptimizeRx downgraded to "sector perform" by RBC amid slower growth outlook - MSN
OptimizeRx's SWOT analysis: digital health stock faces headwinds amid growth potential - Investing.com
RBC Capital Downgrades OptimizeRx (OPRX) - MSN
Royal Bank of Canada Reiterates "Sector Perform" Rating for OptimizeRx (NASDAQ:OPRX) - MarketBeat
Barclays PLC Purchases 21,060 Shares of OptimizeRx Co. (NASDAQ:OPRX) - Defense World
Geode Capital Management LLC Sells 20,126 Shares of OptimizeRx Co. (NASDAQ:OPRX) - Defense World
OMNIQ Corporation Issues Press Release on January 6th, 2025OMNIQ CORP. recently released a notable press release on January 6, 2025. The content of this press release was unveiled as part of the company’s submission of a Form 8-K filing to the Securi - Defense World
Inseego Appoints Juho Sarvikas as Chief Executive Officer and Announces New Board MembersSAN DIEGO – Inseego Corp. (NASDAQ: INSG) has recently announced the appointment of Juho Sarvikas as Chief Executive Officer, effective January 6, 2025. Th - Defense World
White Gold (CVE:WGO) Shares Down 0.9% – What’s Next? - Defense World
Shepherd Ave Capital Acquisition Co. Unit’s Quiet Period Will Expire on January 14th (NASDAQ:SPHAU) - Defense World
OptimizeRx Co. (NASDAQ:OPRX) Receives $9.19 Average Target Price from Brokerages - Defense World
Keyence (OTCMKTS:KYCCF) Shares Up 0.5% – Here’s What Happened - Defense World
OptimizeRx Co. (NASDAQ:OPRX) Receives $9.19 Consensus Target Price from Brokerages - MarketBeat
Reviewing OptimizeRx (NASDAQ:OPRX) & Maximus (NYSE:MMS) - Defense World
Glucotrack Receives Notice from Nasdaq Regarding Bid Price Rule Compliance**Washington, D.C., December 31, 2024 – Glucotrack, Inc. (NASDAQ: GCTK) recently received notification from the Nasdaq Stock Market LLC (“Nasdaq”) concerning its bid price f - Defense World
Palomar Holdings, Inc. Extends CEO Mac Armstrong’s Employment AgreementPalomar Holdings, Inc. (NASDAQ: PLMR) announced on December 23, 2024, that the company has entered into an executive employment agreement with Mac Armstrong, the Chi - Defense World
AmpliTech Group Enters Securities Purchase Agreement, Announces OfferingOn December 27, 2024, AmpliTech Group, Inc. (NASDAQ: AMPG) disclosed in a Form 8-K filing with the Securities and Exchange Commission that it has entered into a Securities P - Defense World
FACT II Acquisition Corp. Unit’s (NASDAQ:FACTU) Quiet Period To End on January 6th - Defense World
TRU Precious Metals (CVE:TRU) Shares Down 25% – Should You Sell? - Defense World
OptimizeRx price target lowered to $13 from $17 at B. Riley - Yahoo Finance
Lake Street reiterates Buy on OptimizeRx after ‘surprising’ CEO departure - Yahoo Finance
OptimizeRx’s (OPRX) Buy Rating Reaffirmed at Lake Street Capital - Defense World
OptimizeRx (NASDAQ:OPRX) Given New $13.00 Price Target at B. Riley - Defense World
Stifel maintains Buy rating on OptimizeRX stock citing shift to consistent growth strategy - Investing.com India
Lake Street holds OptimizeRX stock at Buy list despite CEO exit - Investing.com Australia
OptimizeRx's (OPRX) Buy Rating Reaffirmed at Lake Street Capital - MarketBeat
Lake Street holds OptimizeRX stock at Buy list despite CEO exit By Investing.com - Investing.com South Africa
OptimizeRx Corp. Announces Chief Executive Officer Changes - Marketscreener.com
OptimizeRX stock retains Buy rating as company transitions to new leadership team - Investing.com
OptimizeRx CEO to step down, interim successor named By Investing.com - Investing.com Australia
OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO - EIN News
OptimizeRx CEO to step down, interim successor named - Investing.com
OptimizeRx (NASDAQ:OPRX) Research Coverage Started at Stephens - Defense World
OptimizeRx CEO Steps Down After 9-Year Growth Era; Company Projects Strong 2024 Outlook - StockTitan
OptimizeRx Co. (NASDAQ:OPRX) Stake Increased by BNP Paribas Financial Markets - Defense World
Optimizerx Corp Stock (OPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Optimizerx Corp Stock (OPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Odence-Ford Marion | General Counsel and CCO |
Dec 19 '24 |
Option Exercise |
0.00 |
3,927 |
0 |
28,383 |
| Silvestro Stephen L | Chief Commercial Officer |
Dec 19 '24 |
Option Exercise |
0.00 |
6,546 |
0 |
83,424 |
| Besch Doug | Chief Product Officer |
Dec 19 '24 |
Option Exercise |
0.00 |
1,964 |
0 |
12,160 |
| Stelmakh Edward | CFO/COO |
Dec 19 '24 |
Option Exercise |
0.00 |
5,237 |
0 |
38,603 |
| FEBBO WILLIAM J | CEO |
Dec 12 '24 |
Buy |
5.01 |
20,000 |
100,220 |
601,253 |
| Odence-Ford Marion | General Counsel and CCO |
Nov 08 '24 |
Option Exercise |
0.00 |
1,785 |
0 |
24,980 |
| Stelmakh Edward | CFO/COO |
Oct 11 '24 |
Option Exercise |
0.00 |
8,222 |
0 |
35,432 |
| Stelmakh Edward | CFO/COO |
Oct 03 '24 |
Option Exercise |
0.00 |
16,622 |
0 |
31,387 |
| Odence-Ford Marion | General Counsel and CCO |
Oct 03 '24 |
Option Exercise |
0.00 |
6,649 |
0 |
25,147 |
| Silvestro Stephen L | Chief Commercial Officer |
Oct 03 '24 |
Option Exercise |
0.00 |
6,649 |
0 |
79,495 |
8.66%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):